Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7625MR)

This product GTTS-WQ7625MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7625MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7361MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ3340MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ4033MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ13855MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ7870MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ1648MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ6086MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ2910MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG827
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW